Pharmacogenetic genotype and phenotype frequencies in a large Danish population-based case-cohort sample
暂无分享,去创建一个
T. Werge | O. Mors | P. Mortensen | A. Børglum | M. Nordentoft | D. Hougaard | C. Gasse | J. Bybjerg-Grauholm | M. Bækvad-Hansen | C. Lunenburg | J. Thirstrup | Marie Bækvad-Hansen | J. Thirstrup
[1] D. Müller,et al. Frequencies of Genetic Polymorphisms of Clinically Relevant Gene-Drug Pairs in a German Psychiatric Inpatient Population , 2020, Pharmacopsychiatry.
[2] T. Werge,et al. Effect of Routine Cytochrome P450 2D6 and 2C19 Genotyping on Antipsychotic Drug Persistence in Patients With Schizophrenia: A Randomized Clinical Trial. , 2020, JAMA network open.
[3] Bahareh Behroozi Asl,et al. Review and Consensus on Pharmacogenomic Testing in Psychiatry , 2020, Pharmacopsychiatry.
[4] C. Gasse,et al. Pharmacogenetics in psychiatric care, a call for uptake of available applications , 2020, Psychiatry Research.
[5] M. Relling,et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group , 2019, Clinical and translational science.
[6] M. Ingelman-Sundberg,et al. Development of the PGx‐Passport: A Panel of Actionable Germline Genetic Variants for Pre‐Emptive Pharmacogenetic Testing , 2019, Clinical pharmacology and therapeutics.
[7] Deepak L. Bhatt,et al. CYP2C19 pharmacogenetics versus standard of care dosing for selecting antiplatelet therapy in patients with coronary artery disease: A meta‐analysis of randomized clinical trials , 2018, Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions.
[8] A. V. van Kuilenburg,et al. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. , 2018, The Lancet. Oncology.
[9] K. Byron,et al. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes , 2018, Journal of Neural Transmission.
[10] Richard M Weinshilboum,et al. Pharmacogenomics: Precision Medicine and Drug Response , 2017, Mayo Clinic proceedings.
[11] K. Sangkuhl,et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update , 2017, Clinical pharmacology and therapeutics.
[12] M. Daly,et al. The iPSYCH2012 case–cohort sample: new directions for unravelling genetic and environmental architectures of severe mental disorders , 2017, Molecular Psychiatry.
[13] M O Karlsson,et al. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium , 2017, Clinical pharmacology and therapeutics.
[14] Matthias Samwald,et al. Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available , 2016, PloS one.
[15] Melissa A. Basford,et al. Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network , 2016, Clinical pharmacology and therapeutics.
[16] M. Daly,et al. High-Quality Exome Sequencing of Whole-Genome Amplified Neonatal Dried Blood Spot DNA , 2016, PloS one.
[17] C. Altar,et al. Combinatorial pharmacogenomic guidance for psychiatric medications reduces overall pharmacy costs in a 1 year prospective evaluation , 2015, Current medical research and opinion.
[18] Michael R. Jablonski,et al. The clinical validity and utility of combinatorial pharmacogenomics: Enhancing patient outcomes , 2015, Applied & translational genomics.
[19] Erica A. Bowton,et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing , 2013, Clinical pharmacology and therapeutics.
[20] J J Swen,et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Tricyclic Antidepressants , 2013, Clinical pharmacology and therapy.
[21] D. Geschwind,et al. Sex differences in autism spectrum disorders. , 2013, Current opinion in neurology.
[22] H. Guchelaar,et al. Pharmacogenetics: From Bench to Byte— An Update of Guidelines , 2011, Clinical pharmacology and therapeutics.
[23] T. Klein,et al. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.
[24] H. Guchelaar,et al. Pharmacogenetics: From Bench to Byte , 2008, Clinical pharmacology and therapeutics.
[25] Joseph Biederman,et al. The worldwide prevalence of ADHD: is it an American condition? , 2003, World psychiatry : official journal of the World Psychiatric Association.
[26] A. Lukowiak,et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: A randomized clinical trial demonstrating clinical utility. , 2018, Journal of psychiatric research.
[27] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[28] M Ingelman-Sundberg,et al. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity , 2005, The Pharmacogenomics Journal.